MGMT inhibition regulates radioresponse in GBM, GSC, and melanoma

Hong Shik Yun,Tamalee R. Kramp,Kamalakannan Palanichamy,Philip J. Tofilon,Kevin Camphausen

DOI: https://doi.org/10.1038/s41598-024-61240-x

IF: 4.6

2024-05-30

Scientific Reports

Abstract:Radiotherapy is the standard treatment for glioblastoma (GBM), but the overall survival rate for radiotherapy treated GBM patients is poor. The use of adjuvant and concomitant temozolomide (TMZ) improves the outcome; however, the effectiveness of this treatment varies according to MGMT levels. Herein, we evaluated whether MGMT expression affected the radioresponse of human GBM, GBM stem-like cells (GSCs), and melanoma. Our results indicated a correlation between MGMT promoter methylation status and MGMT expression. MGMT-producing cell lines ACPK1, GBMJ1, A375, and MM415 displayed enhanced radiosensitivity when MGMT was silenced using siRNA or when inhibited by lomeguatrib, whereas the OSU61, NSC11, WM852, and WM266-4 cell lines, which do not normally produce MGMT, displayed reduced radiosensitivity when MGMT was overexpressed. Mechanistically lomeguatrib prolonged radiation-induced γ H2AX retention in MGMT-producing cells without specific cell cycle changes, suggesting that lomeguatrib-induced radiosensitization in these cells is due to radiation-induced DNA double-stranded break (DSB) repair inhibition. The DNA-DSB repair inhibition resulted in cell death via mitotic catastrophe in MGMT-producing cells. Overall, our results demonstrate that MGMT expression regulates radioresponse in GBM, GSC, and melanoma, implying a role for MGMT as a target for radiosensitization.

multidisciplinary sciences

What problem does this paper attempt to address?

The paper attempts to address the issue of how the expression of MGMT (O6-methylguanine-DNA methyltransferase) affects the response of glioblastoma (GBM), glioblastoma stem-like cells (GSCs), and melanoma to radiotherapy. Specifically, the researchers evaluated whether modulating MGMT expression in these cell lines through molecular biology methods could alter their sensitivity to radiotherapy.

The background of the study points out that although radiotherapy is the standard treatment for glioblastoma, the overall survival rate of patients remains very low. The use of adjuvant and concurrent temozolomide (TMZ) can improve treatment outcomes, but its effectiveness is influenced by MGMT levels. MGMT is a crucial DNA repair protein that can repair DNA damage caused by alkylating agents, leading to tumor resistance to treatment. The expression of MGMT is regulated by the methylation status of its promoter region, which is an important biomarker for predicting the response of GBM patients to TMZ treatment.

Therefore, the main objective of this study is to experimentally verify the specific impact of MGMT expression on the response of glioblastoma, glioblastoma stem-like cells, and melanoma to radiotherapy, aiming to provide new strategies to enhance the sensitivity of these tumors to radiotherapy. The study results indicate that MGMT expression can indeed regulate the response of these tumor cells to radiotherapy, suggesting that MGMT may be a potential target for improving the effectiveness of radiotherapy.